高血压药物治疗与非药物治疗研究进展  

Research progress in pharmacological and non-pharmacological treatments of hypertension

作　　者：徐建飞 林利[2] XU Jianfei;LIN Li(Tongji University School of Medicine,Shanghai 200092,China;Department of Cardiovascular Medicine,Dongfang Hospital Affiliated to Tongji University,Shanghai 200120,China)

机构地区：[1]同济大学医学院,上海200092 [2]同济大学附属东方医院心血管内科,上海200120

出　　处：《中国临床药理学与治疗学》2022年第4期433-441,共9页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：国家自然科学基金(81570237,81870197);上海市浦东临床顶级学科项目(PWYgf2021-01)。

摘　　要：高血压是全世界最常见的慢性非传染性疾病,也是诱发心脑血管疾病最重要的危险因素。目前高血压治疗达标控制率不足50%,在很大程度上仍然未被有效的治疗管理。尽管在过去的四十年中进行了大量的临床研究和试验,但新型抗高血压药物的研究进展并不尽如人意。本综述讨论了近年来高血压患者药物治疗和非药物治疗方面的进展,并可能在未来为临床高血压治疗提供新方案。Hypertension is the most common chronic non-communicable disease in the world and the most important risk factor for cardiovascular and cerebrovascular diseases.At present,the control rate of hypertension treatment standard is less than 50%,and it is still not effectively managed to a large extent.Despite numerous clinical studies and trials over the past four decades,the progress of new antihypertensive drugs has not been satisfactory.This review discusses recent advances in pharmacological and non-pharmacological treatments for patients with hypertension,and may provide new options for clinical hypertension treatment in the future.

关 键 词：高血压 药物治疗 脑啡肽酶抑制剂 GLP-1 

分 类 号：R544.1[医药卫生—心血管疾病] R972.4[医药卫生—内科学]